Emerging trends in plasma‐free manufacturing of recombinant protein therapeutics expressed in mammalian cells

Mammalian cells are the expression system of choice for therapeutic proteins, especially those requiring complex post‐translational modifications. Traditionally, these cells are grown in medium supplemented with serum and other animal‐ or human‐derived components to support viability and productivity. Such proteins are also typically added as excipients and stabilizers in the final drug formulation. However, the transmission of hepatitis B in the 1970s and of hepatitis C and HIV in the 1980s through plasma‐derived factor VIII concentrates had catastrophic consequences for hemophilia patients. Thus, due to regulatory concerns about the inherent potential for transmission of infectious agents as well as the heterogeneity and lack of reliability of the serum supply, a trend has emerged to eliminate the use of plasma‐derived additives in the production and formulation of recombinant protein therapeutics. This practice began with products used in the treatment of hemophilia and is progressively expanding throughout the entire industry. The plasma‐free method of producing recombinant therapeutics is accomplished by the use of both cell culture media and final product formulations that do not contain animal‐ or human‐derived additives. A number of recombinant therapeutic proteins for the treatment of several different diseases have been produced by plasma‐free processes, with the objective of improving safety by eliminating blood‐borne pathogens or by reducing immunogenicity. This review describes the factors that drove the development of plasma‐free protein therapeutics and provides examples of advances in manufacturing that have made possible the removal of human and animal‐derived products from all steps of recombinant protein production.

[1]  L. Dumble,et al.  Creutzfeldt-Jakob legacy for Australian women treated with human pituitary gonadotropins , 1992, The Lancet.

[2]  K John Morrow,et al.  Advances in antibody manufacturing using mammalian cells. , 2007, Biotechnology annual review.

[3]  David R. Olsen,et al.  Stabilization of proteins by recombinant human gelatins. , 2007, Journal of pharmaceutical sciences.

[4]  E. Brown,et al.  Molecular cloning of a cDNA encoding human antihaemophilic factor. 1984. , 1992, Biotechnology.

[5]  Y. Agid,et al.  Creutzfeldt-Jakob disease from contaminated growth hormone extracts in France , 1996, Neurology.

[6]  David R. Olsen,et al.  The structure, stability, and complex behavior of recombinant human gelatins. , 2007, Journal of pharmaceutical sciences.

[7]  I. Scharrer,et al.  A Multicenter Pharmacosurveillance Study for the Evaluation of the Efficacy and Safety of Recombinant Factor VIII in the Treatment of Patients with Hemophilia A , 1997, Thrombosis and Haemostasis.

[8]  A. Swerdlow,et al.  Creutzfeldt-Jakob disease in United Kingdom patients treated with human pituitary growth hormone , 2003, Neurology.

[9]  M. Head,et al.  Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient , 2004, The Lancet.

[10]  T. Dingermann.  Recombinant therapeutic proteins: Production platforms and challenges , 2008, Biotechnology journal.

[11]  B Stubinski,et al.  Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results , 2009, Multiple sclerosis.

[12]  Hilgartner Mw.  The need for recombinant factor VIII: historical background and rationale. , 1991 .

[13]  Xiaoming Yang,et al.  Implementation of advanced technologies in commercial monoclonal antibody production , 2008, Biotechnology journal.

[14]  Mrc Prion.  Kuru in the 21st century-an acquired human prion disease with very long incubation periods , 2006 .

[15]  N. Hunter,et al.  Prion diseases are efficiently transmitted by blood transfusion in sheep. , 2008, Blood.

[16]  R. Holman,et al.  Creutzfeldt-Jakob disease in the United States, 1979-1994: using national mortality data to assess the possible occurrence of variant cases. , 1996, Emerging infectious diseases.

[17]  D. Morens,et al.  Variant Creutzfeldt-Jakob disease and the acquired and transmissible spongiform encephalopathies. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  B. Evatt.  Infectious disease in the blood supply and the public health response. , 2006, Seminars in hematology.

[19]  T. Peters.  2 - The Albumin Molecule: Its Structure and Chemical Properties , 1995 .

[20]  J. Oldenburg,et al.  Frequency of contamination of coagulation factor concentrates with novel human parvovirus PARV4 , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[21]  Martin Clynes,et al.  The role of recombinant proteins in the development of serum-free media , 2006, Cytotechnology.

[22]  R. Khabbaz,et al.  Emerging issues in blood safety. , 1998, Infectious disease clinics of North America.

[23]  Michael Butler,et al.  Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals , 2005, Applied Microbiology and Biotechnology.

[24]  B. Erstad.  Viral Infectivity of Albumin and Plasma Protein Fraction , 1996, Pharmacotherapy.

[25]  S. Baylis,et al.  Human parvovirus PARV4 in clotting factor VIII concentrates , 2007, Vox sanguinis.

[26]  W. Heneine,et al.  Evidence of porcine endogenous retroviruses in porcine factor VIII and evaluation of transmission to recipients with hemophilia. , 2001, The Journal of infectious diseases.

[27]  X. L. Liu,et al.  Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China , 2003, Science.

[28]  G. Wells,et al.  Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. , 2004, Journal of the American Society of Nephrology : JASN.

[29]  F. Wurm.  Production of recombinant protein therapeutics in cultivated mammalian cells , 2004, Nature Biotechnology.

[30]  G. Spotts,et al.  Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK. , 2004, Seminars in hematology.

[31]  A. Shapiro.  Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE®) in the management of hemophilia A , 2007, Vascular health and risk management.

[32]  A. Stein.  Decreasing variability in your cell culture. , 2007, BioTechniques.

[33]  J. Ironside,et al.  Variant Creutzfeldt–Jakob disease: risk of transmission by blood and blood products , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[34]  R. Kaufman,et al.  Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. , 1989, Molecular and cellular biology.

[35]  P. Pellett,et al.  Possible transmission of human herpesvirus‐8 by blood transfusion in a historical United States cohort , 2005, Transfusion.

[36]  Huub Schellekens,et al.  Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. , 2006, Journal of Pharmacy and Science.

[37]  X Lemercinier,et al.  Recombinant human albumin as a stabilizer for biological materials and for the preparation of international reference reagents. , 1998, Biologicals : journal of the International Association of Biological Standardization.

[38]  M. Hilgartner.  The need for recombinant factor VIII: historical background and rationale. , 1991, Seminars in hematology.

[39]  P. Gray,et al.  Insulin‐Like Growth Factor‐I and Transferrin Mediate Growth and Survival of Chinese Hamster Ovary Cells , 2000, Biotechnology progress.

[40]  O. Merten.  Development of serum-free media for cell growth and production of viruses/viral vaccines--safety issues of animal products used in serum-free media. , 2002, Developments in biologicals.

[41]  S. Pipe.  Consideration in hemophilia therapy selection. , 2006, Seminars in hematology.

[42]  A. Pavlou,et al.  The therapeutic antibodies market to 2008. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[43]  B. Keyt,et al.  Structure of human factor VIII , 1984, Nature.

[44]  O. Merten.  Safety issues of animal products used in serum-free media. , 1999, Developments in biological standardization.

[45]  M. Turner,et al.  Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products , 2006, British journal of haematology.

[46]  Gary Walsh,et al.  Biopharmaceutical benchmarks 2010 , 2010, Nature Biotechnology.

[47]  M. Diamond,et al.  Clinical perspectives of emerging pathogens in bleeding disorders , 2006, The Lancet.

[48]  H. Jaffe,et al.  Transmission of human herpesvirus 8 by blood transfusion. , 2007, The New England journal of medicine.

[49]  Merten Ow.  Development of serum-free media for cell growth and production of viruses/viral vaccines--safety issues of animal products used in serum-free media. , 2002 .

[50]  A. Fauci,et al.  The challenge of emerging and re-emerging infectious diseases , 2004, Nature.

[51]  R. Dodd,et al.  Emerging infectious threats to the blood supply. , 2004, Annual review of medicine.

[52]  DavidJ. Evans,et al.  Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy , 1997, The Lancet.

[53]  G. Knutson,et al.  Molecular cloning of a cDNA encoding human antihaemophilic factor , 1984, Nature.

[54]  P. Blumbergs,et al.  Creutzfeldt-Jakob disease in a recipient of human pituitary-derived gonadotrophin. , 1990, Australian and New Zealand journal of medicine.

[55]  Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[56]  R. Dodd.  Current risk for transfusion transmitted infections , 2007, Current opinion in hematology.

[57]  S. Kleinman,et al.  Current and emerging infectious risks of blood transfusions. , 2003, JAMA.

[58]  Ich Topic Q5A.  GUIDANCE FOR INDUSTRY Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin , 2001 .

[59]  Yeon‐Gu Kim,et al.  Assessment of cell engineering strategies for improved therapeutic protein production in CHO cells , 2008, Biotechnology journal.

[60]  D. Costagliola,et al.  Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma‐derived FVIII or FIX concentrate: results from the French haemophilia cohort , 2002, British journal of haematology.

[61]  Laura A Palomares,et al.  Differences in the glycosylation profile of a monoclonal antibody produced by hybridomas cultured in serum‐supplemented, serum‐free or chemically defined media , 2007, Biotechnology and applied biochemistry.

[62]  Chad B. Sandusky,et al.  Serum-free hybridoma culture: ethical, scientific and safety considerations. , 2006, Trends in biotechnology.

[63]  K. Tyler,et al.  Colorado surveillance program for chronic wasting disease transmission to humans: lessons from 2 highly suspicious but negative cases. , 2007, Archives of neurology.

[64]  N. Casadevall,et al.  Pure red-cell aplasia due to anti-erythropoietin antibodies. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[65]  Chronic Wasting Disease of Elk and Deer and Creutzfeldt-Jakob Disease , 2006, Journal of Biological Chemistry.

[66]  S. Froud.  The development, benefits and disadvantages of serum-free media. , 1999, Developments in biological standardization.

[67]  Shuichi Yamamoto,et al.  Diseases of protein aggregation and the hunt for potential pharmacological agents , 2008, Biotechnology journal.

[68]  M. Busch,et al.  Emerging infectious disease issues in blood safety. , 2001, Emerging infectious diseases.

[69]  H. Schatzmayr,et al.  Jungle yellow fever, Rio de Janeiro. , 2001, Emerging infectious diseases.

[70]  Huub Schellekens,et al.  Structure-Immunogenicity Relationships of Therapeutic Proteins , 2004, Pharmaceutical Research.

[71]  C. V. van Duijn,et al.  Creutzfeldt-Jakob disease 38 years after diagnostic use of human growth hormone , 2002, Journal of neurology, neurosurgery, and psychiatry.

[72]  S. Berezenko.  Heterogeneity and oxidation status of commercial human albumin preparations in clinical use. , 2006, Critical care medicine.

[73]  John Collinge,et al.  Kuru in the 21st century—an acquired human prion disease with very long incubation periods , 2006, The Lancet.

[74]  Wim Jiskoot,et al.  A Role for Protein Misfolding in Immunogenicity of Biopharmaceuticals* , 2007, Journal of Biological Chemistry.

[75]  Froud Sj.  The development, benefits and disadvantages of serum-free media. , 1999 .

[76]  W. Hooper,et al.  Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range‐of‐motion limitation , 2004, Transfusion.

[77]  M. Esiri,et al.  Creutzfeldt-Jakob disease in a recipient of human pituitary-derived gonadotrophin: a second case. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[78]  G. Dolan.  Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt–Jakob disease experience , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[79]  T. Gerngross,et al.  Advances in the production of human therapeutic proteins in yeasts and filamentous fungi , 2004, Nature Biotechnology.

[80]  Suvankar Pal,et al.  Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report , 2006, The Lancet.

[81]  L. Valentino,et al.  Blood safety and the choice of anti‐hemophilic factor concentrate , 2006, Pediatric blood & cancer.

[82]  L. Ruiz,et al.  Long-term stabilization of recombinant human interferon alpha 2b in aqueous solution without serum albumin. , 2003, International journal of pharmaceutics.

[83]  Gary Walsh,et al.  Biopharmaceutical benchmarks 2006 , 2006, Nature Biotechnology.

[84]  S. Hino.  TTV, a new human virus with single stranded circular DNA genome , 2002, Reviews in medical virology.

[85]  Gary Walsh,et al.  Biopharmaceutical benchmarks , 2000, Nature Biotechnology.

[86]  A. Shapiro,et al.  Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin‐free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A 1 , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[87]  J Mackenzie,et al.  Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion , 2004, The Lancet.

[88]  Mark Head,et al.  Preclinical variant CJD after blood transfusion in a PRNP codon 129 heterozygous patient , 2004 .